RhumbLine Advisers
LUCD icon

RhumbLine Advisers’s Lucid Diagnostics LUCD Stock Holding History

RhumbLine Advisers’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.9K Sell
48,630
-3,877
-7% -$4.93K ﹤0.01% 3571
2025
Q4 		$57.2K Sell
52,507
-13,622
-21% -$15.2K ﹤0.01% 3612
2025
Q3 		$66.8K Buy
66,129
+3,113
+5% +$3.4K ﹤0.01% 3609
2025
Q2 		$72.5K Buy
+63,016
New +$81.4K ﹤0.01% 3614

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

RhumbLine Advisers's LUCD Position: Q1 2026 in Review

RhumbLine Advisers reduced its Lucid Diagnostics (LUCD) stake by 7.4% in Q1 2026, selling an estimated $4.93K and leaving 48,630 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3571.

RhumbLine Advisers first reported a position in LUCD in Q2 2025 and has held it in 4 quarters since. The position peaked at $72.5K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • RhumbLine Advisers held 48,630 shares of Lucid Diagnostics worth $55.9K as of Q1 2026.
  • RhumbLine Advisers sold 3,877 Lucid Diagnostics shares in Q1 2026, an estimated $4.93K.
  • Lucid Diagnostics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3571 holding.
  • RhumbLine Advisers first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 4 quarters since.
  • RhumbLine Advisers's Lucid Diagnostics position peaked at $72.5K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.